EUVIMEDExplore EUVIMED
Crossref

Discovery and Characterization of Novel Piperidine Derivatives as Potent Cytochrome P450 17A1 Inhibitors for Prostate Cancer Therapy

Angelika Grudzińska iD, Jibira Yakubu iD, Chiara Vigato iD, Therina du Toit iD, Gaia Vanzetti, Radosław Zan, Donatella Boschi iD, Simonetta Oliaro-Bosso iD, Fredrik Björkling iD, Flemming Steen Jørgensen iD, Amit V Pandey iD, Tomasz M Wróbel iD

ChemMedChem · 2026

DOI: 10.1002/cmdc.70336 ↗

At a glance

Journal article in ChemMedChem, 2026. Written by Angelika Grudzińska and 11 co-authors. Institution: Department of Synthesis and Chemical Technology of Pharmaceutical Substances, Medical University of Lublin, Lublin, Poland. Major MEDLINE topics: Piperidines, Steroid 17-alpha-Hydroxylase, Prostatic Neoplasms, Antineoplastic Agents. Cited 1 times so far (Crossref); 46 references. Funded by: Narodowe Centrum Nauki, Cancer Research Switzerland, Fondazione CRT.

AbstractSubjectsBibliographic detailsCiteRelated studies

Abstract (original language)

Castration‐resistant prostate cancer relies on intratumoral androgen synthesis mediated by cytochrome P450 17A1 (CYP17A1). Treatment with the only clinically used CYP17A1 inhibitor, abiraterone, is limited by resistance and side effects, underscoring the urgent need for new CYP17A1 inhibitors with greater selectivity and improved safety profiles. In response to this challenge, we designed, synthesized, and biologically evaluated 30 novel piperidine derivatives. All compounds were initially screened in the H295R cell line to assess their inhibitory activity toward both CYP17A1 and off‐target CYP21A2. Compounds were further evaluated in cell viability assays using prostate cancer cells and a normal prostate cell line. The most potent and selective compounds were subjected to further biological studies: IC 50 determination, steroid profiling, cell migration assay, aldo–keto reductase family 1 member C3 inhibition assays, absorption, distribution, metabolism, and excretion prediction, and solubility testing. Several compounds emerged as the most active and selective leads, highlighting their potential for pharmaceutical development.

Subjects

MeSH terms (MEDLINE)

PiperidinesSteroid 17-alpha-HydroxylaseProstatic NeoplasmsAntineoplastic AgentsDrug DiscoveryCytochrome P-450 Enzyme InhibitorsHumansMaleStructure-Activity RelationshipCell Line, TumorDrug Screening Assays, AntitumorCell SurvivalMolecular StructureDose-Response Relationship, DrugCell MovementCell Proliferation

Author keywords

cancercytochrome P450 17A1inhibitorspiperidinesprostate

Substances

PiperidinesSteroid 17-alpha-HydroxylaseAntineoplastic AgentsCYP17A1 protein, humanCytochrome P-450 Enzyme Inhibitorspiperidine

Authors and institutions

  • Department of Synthesis and Chemical Technology of Pharmaceutical Substances, Medical University of Lublin, Lublin, Poland.
  • Pediatric Endocrinology, University Children's Hospital Bern, Bern, Switzerland.
  • Translational Hormone Research Program, Department of Biomedical Research, University of Bern, Bern, Switzerland.
  • Graduate School for Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland.
  • Department of Drug Science and Technology, University of Turin, Turin, Italy.
  • Department of Nephrology and Hypertension, University Hospital Bern, Inselspital, University of Bern, Bern, Switzerland.

ORCID profiles: Angelika Grudzińska, Jibira Yakubu, Chiara Vigato, Therina du Toit, Donatella Boschi, Simonetta Oliaro-Bosso, Fredrik Björkling, Flemming Steen Jørgensen, Amit V Pandey, Tomasz M Wróbel

Funding

  • Narodowe Centrum Nauki
  • Cancer Research Switzerland
  • Fondazione CRT
  • SF Board Medical Faculty, University of Bern 3010 Bern, Switzerland
  • National Science Centre
  • CRT Foundation

Cite

APA

Grudzińska, A., Yakubu, J., Vigato, C., du Toit, T., Vanzetti, G., Zan, R., Boschi, D., Oliaro-Bosso, S., Björkling, F., Jørgensen, F. S., Pandey, A. V., & Wróbel, T. M. (2026). Discovery and Characterization of Novel Piperidine Derivatives as Potent Cytochrome P450 17A1 Inhibitors for Prostate Cancer Therapy. ChemMedChem. https://doi.org/10.1002/cmdc.70336

Vancouver

Grudzińska A, Yakubu J, Vigato C, du Toit T, Vanzetti G, Zan R, et al. Discovery and Characterization of Novel Piperidine Derivatives as Potent Cytochrome P450 17A1 Inhibitors for Prostate Cancer Therapy. ChemMedChem. 2026. doi:10.1002/cmdc.70336

BibTeX
@article{Grudziska2026,
  author = {Grudzińska, Angelika and Yakubu, Jibira and Vigato, Chiara and du Toit, Therina and Vanzetti, Gaia and Zan, Radosław and Boschi, Donatella and Oliaro-Bosso, Simonetta and Björkling, Fredrik and Jørgensen, Flemming Steen and Pandey, Amit V and Wróbel, Tomasz M},
  title = {Discovery and Characterization of Novel Piperidine Derivatives as Potent Cytochrome P450 17A1 Inhibitors for Prostate Cancer Therapy},
  journal = {ChemMedChem},
  year = {2026},
  doi = {10.1002/cmdc.70336}
}
Start for free →